Despite the millions of dollars spent on target validation and drug optimization in preclinical models, most therapies still fail in phase III clinical trials. Our current model systems, or the way we interpret data from them, clearly do not have sufficient clinical predictive power. Current opinion suggests that this is because the cell lines and xenografts that are commonly used are inadequate models that do not effectively mimic and predict human responses. This has become such a widesprea...Expand abstract
- Publication status:
- Publisher copy:
- American Association for Cancer Research Inc.
- Cancer research
- Publication date:
- Source identifiers:
- Local pid:
- Copyright date:
Cancer cell lines for drug discovery and development.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record